The WHO recommends tenofovir-containing ARVs
for use as PrEP for any person at substantial risk of HIV as part of
combination HIV prevention. More and more countries are considering and using
TDF/3TC as an alternative to TDF/FTC for PrEP, given the limited global
availability of TDF/FTC combined with local challenges including registration,
supply chain and cost. This presentation will help to clarify the
recommendations and the evidence for the use of TDF/3TC for PrEP.
Presenter: Dr Ioannis Hodges-Mameletzis, WHO
Switzerland.
Chair: Dr Heather-Marie Schmidt, WHO and UNAIDS
Regional Office for Asia and the Pacific, Thailand